​

Pharvaris (PHVS) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

PHVS Stock Forecast

Pharvaris (PHVS) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $56.00, with a high of $74.00 and a low of $42.00. This represents a 73.91% increase from the last price of $32.20.

$15 $27 $39 $51 $63 $75 High: $74 Avg: $56 Low: $42 Last Closed Price: $32.2

PHVS Stock Rating

Pharvaris stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (91.67%), 1 Hold (8.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 11 Strong Sell Sell Hold Buy Strong Buy

PHVS Price Target Upside V Benchmarks

TypeNameUpside
StockPharvaris73.91%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts128
Avg Price Target$74.00$58.00$49.50
Last Closing Price$32.20$32.20$32.20
Upside/Downside129.81%80.12%53.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26391--13
May, 26391--13
Apr, 26381--12
Mar, 26281--11
Feb, 26281--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 13, 2026UBS$74.00$31.25136.80%129.81%
Apr 08, 2026Wolfe Research$42.00$27.5652.39%30.43%
Mar 09, 2026RBC Capital$52.00$26.5196.15%61.49%
Dec 04, 2025Oppenheimer$50.00$29.3770.24%55.28%
Dec 04, 2025Debjit ChattopadhyayGuggenheim$39.00$29.3732.79%21.12%
Dec 04, 2025Maxwell SkorMorgan Stanley$41.00$29.3739.60%27.33%
Dec 03, 2025Leerink Partners$38.00$29.3729.38%18.01%
Oct 15, 2025H.C. Wainwright$60.00$20.96186.26%86.34%
Oct 14, 2024Justin KimOppenheimer$42.00$19.73112.87%30.43%
Apr 11, 2024Jonathan WollebenJMP Securities$50.00$22.27124.52%55.28%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 15, 2026CitigroupBuyBuyhold
Apr 08, 2026Wolfe ResearchOutperforminitialise
Dec 04, 2025OppenheimerOutperformOutperformhold
Dec 04, 2025GuggenheimBuyBuyhold
Dec 04, 2025Morgan StanleyOverweightOverweighthold
Dec 03, 2025Leerink PartnersOutperformOutperformhold
Dec 03, 2025Bank of America SecuritiesNeutralNeutralhold
Nov 19, 2025CitigroupMarket OutperformMarket Outperformhold
Oct 15, 2025H.C. WainwrightBuyinitialise
May 14, 2025WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.57-----
Avg Forecast$-2.45$-2.71$-3.14$-3.05$-2.48$-0.31
High Forecast$-1.95$-2.47$-3.01$-2.86$-1.96$-0.31
Low Forecast$-2.69$-3.07$-3.23$-3.19$-2.96$-0.31
Surprise %4.90%-----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$7.56M$43.69M$219.25M
High Forecast---$7.56M$45.17M$219.25M
Low Forecast---$7.56M$42.20M$219.25M
Surprise %------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-98.81M-----
Avg Forecast$-91.67M$-106.40M$-119.81M$-116.16M$-94.49M$-11.88M
High Forecast$-74.81M$-94.88M$-115.47M$-109.98M$-75.27M$-11.88M
Low Forecast$-103.42M$-117.93M$-124.14M$-122.33M$-113.71M$-11.88M
Surprise %7.79%-----

PHVS Forecast FAQ

Is Pharvaris stock a buy?

Pharvaris stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Pharvaris is a favorable investment for most analysts.

What is Pharvaris's price target?

Pharvaris's price target, set by 12 Wall Street analysts, averages $56 over the next 12 months. The price target range spans from $42 at the low end to $74 at the high end, suggesting a potential 73.91% change from the previous closing price of $32.2.

How does Pharvaris stock forecast compare to its benchmarks?

Pharvaris's stock forecast shows a 73.91% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Pharvaris over the past three months?

  • June 2026: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Pharvaris’s EPS forecast?

Pharvaris's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.71, marking a 5.45% increase from the reported $-2.57 in 2023. Estimates for the following years are $-3.14 in 2025, $-3.05 in 2026, $-2.48 in 2027, and $-0.31 in 2028.

What is Pharvaris’s revenue forecast?

Pharvaris's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $7.56M for 2026, $43.69M for 2027, and $219.25M for 2028.

What is Pharvaris’s net income forecast?

Pharvaris's net income forecast for the fiscal year ending in December 2024 stands at $-106M, representing an 7.69% increase from the reported $-98.807M in 2023. Projections indicate $-120M in 2025, $-116M in 2026, $-94.492M in 2027, and $-11.878M in 2028.